Patents Represented by Attorney, Agent or Law Firm Richard P. Ryan
  • Patent number: 5137894
    Abstract: Novel thieno[3,2-c]pyridine derivatives of Formula I, ##STR1## in which Z is glutarimide, are useful antipsychotic agents with reduced side-effect liability.
    Type: Grant
    Filed: December 5, 1991
    Date of Patent: August 11, 1992
    Inventors: James S. New, William L. Christopher
  • Patent number: 5116970
    Abstract: A series of psychotropic heterobicycloalkylpiperazine derivatives having the structure ##STR1## wherein V is a 3- or 4-membered unsaturated chain, containing all carbon atoms when 4-membered, or when a 3-membered chain, V contains an oxygen or sulfur atom as one of the members; R is H or C.sub.1-4 alkyl; W is CH, N, CH.sub.2, or a chemical bond; X is CH, N, SO.sub.2, or CO, with the proviso that both W and X cannot simultaneously be N; and Z is a heteroaromatic ring system. These compounds are useful antipsychotic and/or anxiolytic agents.
    Type: Grant
    Filed: December 20, 1990
    Date of Patent: May 26, 1992
    Inventors: James S. New, William J. Christopher
  • Patent number: 5079234
    Abstract: Certain water-soluble polyanionic organic acid polymers in the weight range of from about 1,000 to 30,000 daltons may be use to inhibit aminoglycoside nephrotoxicity. These polyanionic polymers are homopolymers or copolymers comprised of monomers selected from acrylic, methacryclic, vinylsulfonic and maleic acids; and are in a pharmaceutically acceptable salt form.
    Type: Grant
    Filed: March 23, 1989
    Date of Patent: January 7, 1992
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Donald N. McGregor, Thomas J. Davidson
  • Patent number: 5077293
    Abstract: Certain 1-indolylalkyl-4-(alkoxypyrimidinyl)piperazines of Formula I are useful antidepressant agents. The ##STR1## substituents R.sup.1, R.sup.2 and R.sup.5 are hydrogen or lower alkyl; R.sup.3 and R.sup.4 are hydrogen, alkyl, alkoxy, alkythio, carboxamido, halo, or trifluoromethyl; R.sup.6 is alkoxy; and n is the integer 2 or 3.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: December 31, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventors: David W. Smith, Frank D. Yocca, Joseph P. Yevich, Ronald J. Mattson
  • Patent number: 5055470
    Abstract: A process for protecting brain cells from ischemia and for treating ischemic and degenerative brain disorders. The process involves systemic administration of BMY 14802 or a pharmaceutically acceptable acid addition salt and/or hydrate.
    Type: Grant
    Filed: June 1, 1989
    Date of Patent: October 8, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Christopher G. Boissard, Duncan P. Taylor, Michael S. Eison
  • Patent number: 5015646
    Abstract: "Buspirone hydrochloride can exist in two polymorphic forms and the newly discoverd lower melting form, which is thermodynamically favored at pharmaceutically relevant temperatures, offers advantage in manufacture of buspirone pharmaceutical compositions".
    Type: Grant
    Filed: August 28, 1987
    Date of Patent: May 14, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventor: Jack C. Simms, deceased
  • Patent number: 5011992
    Abstract: Novel substituted benzamides of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A are as defined herein are useful in the treatment of emesis, and particularly chemotherapy-induced emesis in cancer patients. Some of the compounds are also useful in disorders relating to impaired gastric motility.
    Type: Grant
    Filed: August 22, 1989
    Date of Patent: April 30, 1991
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ivo Monkovic, David Willner
  • Patent number: 5011774
    Abstract: A novel process utilizing adenosine deaminase to selectively produce .beta.-(D)-2',3'-dideoxyinosine in high yields from an .alpha.,.beta.-anomeric mixture. .beta.-(D)-2',3'-Dideoxyinosine so produced is useful as an antiviral and antibiotic agent.
    Type: Grant
    Filed: February 28, 1990
    Date of Patent: April 30, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Vittorio Farina, Daniel A. Benigni, Paul R. Brodfuehrer
  • Patent number: 5001130
    Abstract: A series of psychotropic heterobicycloalkylpiperazine derivatives having the structure ##STR1## wherein V is a 3- or 4-membered unsaturated chain, containing all carbon atoms when 4-membered, or when a 3-membered chain, V contains an oxygen or sulfur atom as one of the members; R is H or C.sub.1-4 alkyl; W is CH, N, CH.sub.2, or a chemical bond; X is CH, N, SO.sub.2, or CO, with the proviso that both W and X cannot simultaneously be N; and Z is a heteroaromatic ring system. These compounds are useful antipsychotic and/or anxiolytic agents.
    Type: Grant
    Filed: February 18, 1988
    Date of Patent: March 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: James S. New, William L. Christopher
  • Patent number: 4994460
    Abstract: A series of 5-halopyrimidin-2-ylpiperazinylalkyl derivatives having useful anti-ischemic properties for treatment and prevention of dirorders resulting from brain and/or spinal cord anoxia.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: February 19, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Pierre Dextraze, Joseph P. Yevich
  • Patent number: 4963678
    Abstract: An improved process, suitable for adaption to large-scale manufacture for synthesis of the cerebral function enhancing agent BMY 21502.
    Type: Grant
    Filed: October 27, 1989
    Date of Patent: October 16, 1990
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Gary D. Madding, Joseph L. Minielli, Ronald J. Mattson
  • Patent number: 4956368
    Abstract: Various metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]deca ne-7,9-dione which are particularly useful in the treatment of psychotic disorders, especially derivatives thereof which have been oxygenated at specified sites about the original structure, rearranged compounds, and prodrug formulations of these species. One particularly desired group of compounds have the general Formula I where ##STR1## R.sup.1 is hydrogen, hydroxyl, alkoxy, acyloxy and oxo; R.sup.2 is hydrogen, methyl, hydroxyl, alkoxy, and acyloxy;R.sup.3 is hydrogen, hydroxyl, and methoxy:R.sup.4 is hydrogen, methyl and oxo; andX is S, SO, and SO.sub.2.
    Type: Grant
    Filed: July 24, 1989
    Date of Patent: September 11, 1990
    Assignee: Bristol-Myers Company
    Inventors: Joseph A. Cipollina, Edward H. Ruediger
  • Patent number: 4954502
    Abstract: A series of 1,4-disubstituted piperazine derivatives comprised of indol-3-ylalkyl and substituted pyridin-2-yl substituent groups. These compounds are useful as antidepressant agents.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: September 4, 1990
    Assignee: Bristol-Myers Squibb Company
    Inventors: David W. Smith, Frank D. Yocca, Joseph P. Yevich, Ronald J. Mattson
  • Patent number: 4933343
    Abstract: Buspirone and its pharmaceutically acceptable salts are useful in the clinical improvement of major depression including melancholia.
    Type: Grant
    Filed: January 12, 1989
    Date of Patent: June 12, 1990
    Assignee: Bristol-Myers Company
    Inventors: Jerry Cott, Neil M. Kurtz, Donald S. Robinson
  • Patent number: 4931445
    Abstract: Etoperidone and its pharmaceutically acceptable salts are useful in the treatment of male sexual impotence.
    Type: Grant
    Filed: October 6, 1988
    Date of Patent: June 5, 1990
    Inventors: Irwin Goldstein, Inigo S. de Tejada, Leslie A. Riblet
  • Patent number: 4895846
    Abstract: A series of 1,4-dihydropyridin-3,5-yl dicarboxylic acid amides and esters incorporating an arylpiperazinylalkyl moiety have been prepared possessing the general formula ##STR1## wherein R.sup.4 is cycloalkyl, aryl or hetaryl, generally with electron-withdrawing substituents; R.sup.2 and R.sup.6 are lower alkyl, alkanol, alkoxyalkyl, or alkylaminoalkyl; R.sup.5 is R.sup.2 or arylpiperazinylalkyl; X is O or NH; Y is lower alkylene, alkoxyalkylene, alkylaminoalkylene; and Z is phenyl, substituted pheny, pyridinyl, substituted pyridinyl, or pyrimidinyl. Compounds of this series demonstrate activity as calcium and alpha-adrenergic blockers in in vitro testing and antihypertensive, anti-ischemic, and platelet function inhibiting actions in in vivo screens.
    Type: Grant
    Filed: December 18, 1987
    Date of Patent: January 23, 1990
    Assignee: Bristol-Myers Company
    Inventors: Graham S. Poindexter, Davis L. Temple, Jr.
  • Patent number: 4880930
    Abstract: A series of psychotropic acyclic amide derivatives having the structure ##STR1## wherein R is alkyl, alkenyl, cycloalkyl- and bicycloalkyl-methyl; and Z is a heterocyclic group comprised of pyrimidine, benzisothiazole, thienopyridine, and furopyridine. These compounds are useful antipsychotic and/or anxiolytic agents.
    Type: Grant
    Filed: November 30, 1987
    Date of Patent: November 14, 1989
    Inventor: James S. New
  • Patent number: 4859666
    Abstract: Tetrahydro-isoxazolo[4,5-d]azepine derivatives possess antiamnesic properties and are cognition enhancers.
    Type: Grant
    Filed: July 6, 1988
    Date of Patent: August 22, 1989
    Assignee: Bristol-Myers Company
    Inventors: Michael S. Eison, Povl Krogsgaard-Larsen
  • Patent number: 4849527
    Abstract: A process for resolving a racemic modification of .beta.-adrenergic aryl- or hetaryl-oxypropanolamines such as (.+-.)-2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-)-1,1-dimethylethyl]amino]propox y]benzonitrile into its individual enantiomers is described. The process comprises converting the racemic modification into a pair of diastereomeric urea derivativesby reaction with a chiral aralkylisocyanate; separation into the individual diastereomers; and facile regeneration of the starting amine by cleavage of the intermediate urea compound using hydrazine. This final step is improved by the addition of an .alpha.-keto carboxylic acid, such as pyruvic acid, which functions as a scavenger of nucleophilic by-products.
    Type: Grant
    Filed: March 30, 1988
    Date of Patent: July 18, 1989
    Assignee: Bristol-Myers Company
    Inventors: Ronald D. Dennis, Terence M. Dolak, William E. Kreighbaum
  • Patent number: 4847252
    Abstract: Tiospirone and its pharmaceutically acceptable salts are useful in alleviation of vascular or vascular-related headaches such as migraine, cluster, muscle-contraction, and combined headaches.
    Type: Grant
    Filed: October 25, 1988
    Date of Patent: July 11, 1989
    Assignee: Bristol-Myers Company
    Inventors: Davis L. Temple, Michael F. Rafferty, Michael S. Eison, Stacy N. Suberg